MedTrace Logo

Cardiopulmonary Capacity in Elderly With Different Ranges of Serum Thyroid Stimulating Hormone

NCT01849861 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 200

Last updated 2013-05-13

No results posted yet for this study

Summary

The purpose of this study is to correlate in an elderly population (≥ 65 years), the different levels of serum TSH, with cardiopulmonary capacity, quality of life, depressive symptoms and cognition. And assess whether the increased serum TSH to the upper half of the normal range, through the use of antithyroid drugs, is associated with improvements in these parameters.

Conditions

  • Healthy

Interventions

DRUG

Methimazole

Patients with serum TSH initially on the 1st. Quartile (TSH: 0.4 to 1.0 mIU / ml) will receive treatment with Methimazole (initial dose of 5mg/day) with the goal of raising the TSH values to range between 2.0 and 4.0 mIU / ml (the half upper range of normal). After six months with TSH in the target range (2.0 and 4.0 mIU / ml), these patients will be subjected to the same examination protocol performed at baseline and assessed to the effects of treatment on outcome variables. Variables considered in this study: * TSH and FT4 * Questionnaire of Quality of life for older adults (WHOQOL-OLD) * Mini-Mental State Examination * Geriatric Depression Scale * Cardiopulmonary exercise testing - cardiopulmonary capacity

Sponsors & Collaborators

  • Conselho Nacional de Desenvolvimento Científico e Tecnológico

    collaborator OTHER_GOV

  • Universidade Federal do Rio de Janeiro

    lead OTHER

Principal Investigators

  • Dhiãnah SO Chachamovitz · Universidade Federal do Rio de Janeiro

Study Design

Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2011-09-30
Primary Completion
2014-07-31
Completion
2014-09-30

Countries

  • Brazil

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01849861 on ClinicalTrials.gov